Literature DB >> 12556488

Erythroid differentiation sensitizes K562 leukemia cells to TRAIL-induced apoptosis by downregulation of c-FLIP.

Ville Hietakangas1, Minna Poukkula, Kaisa M Heiskanen, Jarkko T Karvinen, Lea Sistonen, John E Eriksson.   

Abstract

Regulation of the apoptotic threshold is of great importance in the homeostasis of both differentiating and fully developed organ systems. Triggering differentiation has been employed as a strategy to inhibit cell proliferation and accelerate apoptosis in malignant cells, in which the apoptotic threshold is often characteristically elevated. To better understand the mechanisms underlying differentiation-mediated regulation of apoptosis, we have studied death receptor responses during erythroid differentiation of K562 erythroleukemia cells, which normally are highly resistant to tumor necrosis factor (TNF) alpha-, FasL-, and TRAIL-induced apoptosis. However, upon hemin-mediated erythroid differentiation, K562 cells specifically lost their resistance to TNF-related apoptosis-inducing ligand (TRAIL), which efficiently killed the differentiating cells independently of mitochondrial apoptotic signaling. Concomitantly with the increased sensitivity, the expression of both c-FLIP splicing variants, c-FLIP(L) and c-FLIP(S), was downregulated, resulting in an altered caspase 8 recruitment and cleavage in the death-inducing signaling complex (DISC). Stable overexpression of both c-FLIP(L) and c-FLIP(S) rescued the cells from TRAIL-mediated apoptosis with isoform-specific effects on DISC-recruited caspase 8. Our results show that c-FLIP(L) and c-FLIP(S) potently control TRAIL responses, both by distinct regulatory features, and further imply that the differentiation state of malignant cells determines their sensitivity to death receptor signals.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12556488      PMCID: PMC141136          DOI: 10.1128/MCB.23.4.1278-1291.2003

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  70 in total

1.  FLAME-1, a novel FADD-like anti-apoptotic molecule that regulates Fas/TNFR1-induced apoptosis.

Authors:  S M Srinivasula; M Ahmad; S Ottilie; F Bullrich; S Banks; Y Wang; T Fernandes-Alnemri; C M Croce; G Litwack; K J Tomaselli; R C Armstrong; E S Alnemri
Journal:  J Biol Chem       Date:  1997-07-25       Impact factor: 5.157

2.  Casper is a FADD- and caspase-related inducer of apoptosis.

Authors:  H B Shu; D R Halpin; D V Goeddel
Journal:  Immunity       Date:  1997-06       Impact factor: 31.745

3.  Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors.

Authors:  M Thome; P Schneider; K Hofmann; H Fickenscher; E Meinl; F Neipel; C Mattmann; K Burns; J L Bodmer; M Schröter; C Scaffidi; P H Krammer; M E Peter; J Tschopp
Journal:  Nature       Date:  1997-04-03       Impact factor: 49.962

4.  I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1- and CD-95-induced apoptosis.

Authors:  S Hu; C Vincenz; J Ni; R Gentz; V M Dixit
Journal:  J Biol Chem       Date:  1997-07-11       Impact factor: 5.157

5.  Inhibition of death receptor signals by cellular FLIP.

Authors:  M Irmler; M Thome; M Hahne; P Schneider; K Hofmann; V Steiner; J L Bodmer; M Schröter; K Burns; C Mattmann; D Rimoldi; L E French; J Tschopp
Journal:  Nature       Date:  1997-07-10       Impact factor: 49.962

6.  The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis.

Authors:  N Itoh; S Yonehara; A Ishii; M Yonehara; S Mizushima; M Sameshima; A Hase; Y Seto; S Nagata
Journal:  Cell       Date:  1991-07-26       Impact factor: 41.582

7.  CASH, a novel caspase homologue with death effector domains.

Authors:  Y V Goltsev; A V Kovalenko; E Arnold; E E Varfolomeev; V M Brodianskii; D Wallach
Journal:  J Biol Chem       Date:  1997-08-08       Impact factor: 5.157

8.  An antagonist decoy receptor and a death domain-containing receptor for TRAIL.

Authors:  G Pan; J Ni; Y F Wei; G Yu; R Gentz; V M Dixit
Journal:  Science       Date:  1997-08-08       Impact factor: 47.728

9.  Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors.

Authors:  J P Sheridan; S A Marsters; R M Pitti; A Gurney; M Skubatch; D Baldwin; L Ramakrishnan; C L Gray; K Baker; W I Wood; A D Goddard; P Godowski; A Ashkenazi
Journal:  Science       Date:  1997-08-08       Impact factor: 47.728

10.  The receptor for the cytotoxic ligand TRAIL.

Authors:  G Pan; K O'Rourke; A M Chinnaiyan; R Gentz; R Ebner; J Ni; V M Dixit
Journal:  Science       Date:  1997-04-04       Impact factor: 47.728

View more
  30 in total

1.  ER stress sensitizes cells to TRAIL through down-regulation of FLIP and Mcl-1 and PERK-dependent up-regulation of TRAIL-R2.

Authors:  Rosa Martín-Pérez; Maho Niwa; Abelardo López-Rivas
Journal:  Apoptosis       Date:  2012-04       Impact factor: 4.677

2.  Flow cytometric evaluation of the effects of 3-bromopyruvate (3BP) and dichloracetate (DCA) on THP-1 cells: a multiparameter analysis.

Authors:  Harrie A Verhoeven; Leo J L D van Griensven
Journal:  J Bioenerg Biomembr       Date:  2012-02-09       Impact factor: 2.945

3.  Killing of resistant cancer cells with low Bak by a combination of an antimesothelin immunotoxin and a TRAIL Receptor 2 agonist antibody.

Authors:  Xing Du; Laiman Xiang; Crystal Mackall; Ira Pastan
Journal:  Clin Cancer Res       Date:  2011-08-03       Impact factor: 12.531

4.  The androgen receptor directly targets the cellular Fas/FasL-associated death domain protein-like inhibitory protein gene to promote the androgen-independent growth of prostate cancer cells.

Authors:  Shen Gao; Peng Lee; Hua Wang; William Gerald; Michael Adler; Liying Zhang; Yun-Fang Wang; Zhengxin Wang
Journal:  Mol Endocrinol       Date:  2005-02-24

5.  Live cell evaluation of granzyme delivery and death receptor signaling in tumor cells targeted by human natural killer cells.

Authors:  Alexandra C Vrazo; Adrianne E Hontz; Sarah K Figueira; Braeden L Butler; Julie M Ferrell; Brock F Binkowski; Jinzhu Li; Kimberly A Risma
Journal:  Blood       Date:  2015-06-29       Impact factor: 22.113

6.  The transcription factor Wilms tumor 1 confers resistance in myeloid leukemia cells against the proapoptotic therapeutic agent TRAIL (tumor necrosis factor α-related apoptosis-inducing ligand) by regulating the antiapoptotic protein Bcl-xL.

Authors:  Hima Bansal; Theresea Seifert; Carlos Bachier; Manjeet Rao; Gail Tomlinson; Swaminathan Padmanabhan Iyer; Sanjay Bansal
Journal:  J Biol Chem       Date:  2012-08-16       Impact factor: 5.157

7.  Activation of the Akt survival pathway contributes to TRAIL resistance in cancer cells.

Authors:  Jing Xu; Jun-Ying Zhou; Wei-Zen Wei; Gen Sheng Wu
Journal:  PLoS One       Date:  2010-04-19       Impact factor: 3.240

8.  Targeting PP2A inhibits the growth of triple-negative breast cancer cells.

Authors:  Mohammed Hafiz Uddin; Julio M Pimentel; Madhumita Chatterjee; Joshu E Allen; Zhengping Zhuang; Gen Sheng Wu
Journal:  Cell Cycle       Date:  2020-02-03       Impact factor: 4.534

Review 9.  Cellular FLICE-inhibitory protein: an attractive therapeutic target?

Authors:  Olivier Micheau
Journal:  Expert Opin Ther Targets       Date:  2003-08       Impact factor: 6.902

10.  TAK1 is required for survival of mouse fibroblasts treated with TRAIL, and does so by NF-kappaB dependent induction of cFLIPL.

Authors:  Josep Maria Lluis; Ulrich Nachbur; Wendy Diane Cook; Ian Edward Gentle; Donia Moujalled; Maryline Moulin; Wendy Wei-Lynn Wong; Nufail Khan; Diep Chau; Bernard Andrew Callus; James Edward Vince; John Silke; David Lawrence Vaux
Journal:  PLoS One       Date:  2010-01-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.